Providence Health & Services

This treatment program tests a personalized cell therapy for people with advanced pancreatic or colorectal cancers that have a specific genetic mutation (KRAS G12D). Patients' own immune cells are collected, genetically engineered to recognize and attack the cancer, and then infu…

This phase 2 trial tests whether adding an immunotherapy drug called IRX 2 to standard pembrolizumab (Keytruda) and chemotherapy can improve outcomes for people with triple-negative breast cancer. The study involves 12 participants who receive the combination before surgery. The …

This early-phase study tests a personalized treatment for people with incurable cancers. Doctors take a patient's own immune cells, engineer them to recognize unique markers on their tumor, and infuse them back along with drugs that boost the immune response. The goal is to see i…

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy is safe and works for people with metastatic triple negative breast cancer, a hard-to-treat form. 29 adults with advanced cancer that had spread or could not be removed by surgery took …

This study compares two treatments for metastatic melanoma that has spread: high-dose Interleukin-2 (IL-2) alone versus IL-2 combined with targeted radiation (SBRT). The goal is to see if adding radiation helps shrink tumors better than IL-2 alone. The trial enrolled 44 adults wi…

This phase 2 trial tests whether adding the experimental drug galunisertib to standard chemoradiation can improve outcomes for people with locally advanced rectal cancer. About 50 participants will receive the combination over 8 weeks, followed by surgery. Researchers will also s…

This early-phase trial tests a new approach for people with advanced epithelial cancers that cannot be cured. Researchers take a patient's own immune cells, genetically engineer them to recognize unique cancer markers, and infuse them back along with two drugs that boost the immu…

This study tests a combination of three drugs (nivolumab, bicalutamide, and ipilimumab) in 30 people with advanced HER2-negative breast cancer that has spread. The goal is to see if this chemo-free approach can control the disease for at least 24 weeks. Participants must have mea…

This early-phase study tests a new two-drug combination for people with advanced neuroendocrine tumors (NETs) that have stopped responding to standard treatments. The drugs are cabozantinib (a targeted therapy pill) and Lu-177 DOTATATE (a radioactive treatment that seeks out tumo…

This study tests whether two targeted drugs (encorafenib and binimetinib) with or without an immunotherapy drug (nivolumab) can shrink or slow advanced thyroid cancer that has spread and no longer responds to standard radioactive iodine treatment. About 24 adults with a specific …

This early-phase study tests a new immune-boosting drug (DPX-Survivac) combined with hormone therapy, with or without low-dose radiation or chemotherapy, in women with hormone receptor-positive, HER2-negative breast cancer. The main goal is to check safety before standard surgery…

This phase 2 trial tests giving the immunotherapy drug pembrolizumab (Keytruda) along with a short course of targeted radiation before surgery for people with advanced head and neck cancer. The goal is to see if this combination can shrink tumors more effectively and help preserv…

This study is for people with advanced non-small cell lung cancer who have already tried other treatments. Researchers are testing whether adding an experimental drug called MK-3475 to standard chemotherapy (gemcitabine) is safe and what dose works best. The goal is to control th…

This trial tests a new approach for people with advanced cancers that have a specific genetic change called KRAS G12V. Patients receive their own immune cells that have been genetically modified to recognize and attack the cancer. They also get chemotherapy and an immunotherapy d…

This study looks at whether a special cooling cap, called the Amma system, can help women with early-stage breast cancer keep more of their hair during chemotherapy. Fifteen women will use the cap during each chemo session and answer questions about how satisfied they are. The go…

This study is for 18 adults with head and neck cancer who are already scheduled for surgery. Researchers want to see if it is safe and possible to inject the drug ipilimumab directly into the tumor a few weeks before the operation. The main goal is to check if this approach delay…